The content on this site is intended for healthcare professionals only
Prof Le Gouill speaks with ecancertv at ASH 2016 about the outcomes of the LYMA trial in France and Belgium, in which rituximab was assessed as part of maintenance therapy for young mantle cell lymphoma patients.
He describes the addition of rituximab as worthy of being a new standard of care in this setting, with extensions to patient EFS, PFS and overall survival.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Optimising the personalisation of prostate cancer treatment
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
EHA 2024: Multiple myeloma roundup
